Press Releases April 15, 2026 08:00 PM

OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026

OrthoPediatrics Corp. Announces Q1 2026 Financial Results Release Date and Conference Call

By Hana Yamamoto KIDS
OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
KIDS

OrthoPediatrics Corp., a company focused on pediatric orthopedics, announced it will release its Q1 2026 financial results on April 30, 2026, followed by a conference call to discuss the results. The company markets over 85 products serving pediatric orthopedic needs globally with distribution in the US and over 75 other countries.

Key Points

  • OrthoPediatrics will report first quarter 2026 financial results on April 30, 2026, after market close.
  • The company focuses exclusively on pediatric orthopedic products including trauma, deformity, scoliosis, and sports medicine.
  • OrthoPediatrics has a global distribution network across the US and more than 75 countries, emphasizing its market reach.
  • The sectors impacted include healthcare, specifically orthopedic medical devices and pediatric healthcare markets.

WARSAW, Ind., April 16, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2026 financial results on Thursday, April 30, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, April 30, 2026 at 4:30 p.m. ET to discuss the results.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 85 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Trip Taylor
Gilmartin Group
[email protected]
415-937-5406


Risks

  • Financial results could underperform market expectations, negatively impacting stock price and investor sentiment.
  • Potential market or regulatory challenges in global markets could affect product sales and distribution.
  • Dependence on continued advancements and acceptance in pediatric orthopedic treatment to maintain growth trajectory.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026